Neonatal Fc receptor (FcRn) antagonist
Rozanolixizumab
Brand names: Rystiggo
Adult dose
Dose: Weekly SC for 6 weeks per cycle (weight-based) — specialist
Route: SC
Frequency: weekly cycle
Clinical pearls
- Generalised myasthenia gravis (anti-AChR or anti-MuSK positive)
- Specialist neurology — vaccinate before
Contraindications
- Active serious infection
- Hypersensitivity
Side effects
- Headache
- Infections
- Diarrhoea
- Pyrexia
- Aseptic meningitis (rare)
- IgG reduction
Interactions
- Live vaccines
- Other IgG-targeting therapies
Monitoring
- IgG
- Infections
- Symptoms (MG-ADL)
Reference: BNF; NICE TA917; SmPC; https://bnf.nice.org.uk/drugs/rozanolixizumab/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- Glucose Infusion Rate (GIR) Calculator · Glucose Management
- APGAR Score · Neonatal Assessment
- Hour-Specific Bilirubin Risk Assessment (Bhutani Nomogram) · Neonatal Jaundice
- Finnegan Neonatal Abstinence Scoring Tool (FNAST) · Neonatal Abstinence Syndrome
- Silverman-Andersen Retraction Score · Respiratory Distress
- New Ballard Score — Gestational Age Assessment · Gestational Age
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS